World Liberty Financial (WLFI) has appointed Ryan Ballantyne, who led the institutional client strategy division at Coinbase, as its Chief Business Officer. Ballantyne will oversee WLFI's global business strategy and partnerships. WLFI announced Ballantyne's joining in an official post on X. He has experience supporting the introduction of digital asset finance, trading, and custody solutions for publicly listed companies and institutional clients at Coinbase. This appointment is seen as part of WLFI's efforts to expand its engagement with institutional and corporate clients, reinforcing its leadership in business partnerships and client relations. WLFI is a project that emphasizes the intersection of DeFi and traditional finance, with an initial supply of 100 billion WLFI tokens proposed. The institutional client business involves a complex interplay among exchanges, custodians, payment infrastructure, and data providers. Ballantyne's previous experience is noteworthy as it relates to corporate finance, digital asset custody, and discussions on stablecoin payment infrastructure in South Korea. This announcement pertains to executive appointments and roles, and the impact on WLFI token prices or trading volumes has not been confirmed.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

























Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.




